Search filters

Filters

Clear All

Phase

  • 2
  • 3
  • 5
  • 3
  • 20
  • 33
  • 24
  • 1
  • 2
  • 30
  • 32
  • 1
  • 4
  • 29

Found 33 hematology trials

A listing of hematology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

API Push Trial without Cancer condition at attribute

All genders
To evaluate the efficacy of ONC201 administered following radiotherapy in participants with H3 K27Mmutant diffuse glioma. To assess plasma concentrations and estimate PK parameters for ONC201. To evaluate the efficacy of ONC201 using RANO-LGG criteria. To evaluate the impact of ONC201 treatment on health care resource utilization.

Test 20260612

All genders
To evaluate the efficacy of ONC201 administered following radiotherapy in participants with H3 K27Mmutant diffuse glioma. To assess plasma concentrations and estimate PK parameters for ONC201. To evaluate the efficacy of ONC201 using RANO-LGG criteria. To evaluate the impact of ONC201 treatment on health care resource utilization.

Test 20260612-1

All genders
To evaluate the efficacy of ONC201 administered following radiotherapy in participants with H3 K27Mmutant diffuse glioma. To assess plasma concentrations and estimate PK parameters for ONC201. To evaluate the efficacy of ONC201 using RANO-LGG criteria. To evaluate the impact of ONC201 treatment on health care resource utilization.

Test 20260407-1

All genders
To evaluate the efficacy of ONC201 administered following radiotherapy in participants with H3 K27Mmutant diffuse glioma. To assess plasma concentrations and estimate PK parameters for ONC201. To evaluate the efficacy of ONC201 using RANO-LGG criteria. To evaluate the impact of ONC201 treatment on health care resource utilization.

Test 20260831

All genders
To evaluate the efficacy of ONC201 administered following radiotherapy in participants with H3 K27Mmutant diffuse glioma. To assess plasma concentrations and estimate PK parameters for ONC201. To evaluate the efficacy of ONC201 using RANO-LGG criteria. To evaluate the impact of ONC201 treatment on health care resource utilization.

Test 20260910

All genders
To evaluate the efficacy of ONC201 administered following radiotherapy in participants with H3 K27Mmutant diffuse glioma. To assess plasma concentrations and estimate PK parameters for ONC201. To evaluate the efficacy of ONC201 using RANO-LGG criteria. To evaluate the impact of ONC201 treatment on health care resource utilization.

Test 20260915

All genders
To evaluate the efficacy of ONC201 administered following radiotherapy in participants with H3 K27Mmutant diffuse glioma. To assess plasma concentrations and estimate PK parameters for ONC201. To evaluate the efficacy of ONC201 using RANO-LGG criteria. To evaluate the impact of ONC201 treatment on health care resource utilization.

Test 20260915-1

All genders
To evaluate the efficacy of ONC201 administered following radiotherapy in participants with H3 K27Mmutant diffuse glioma. To assess plasma concentrations and estimate PK parameters for ONC201. To evaluate the efficacy of ONC201 using RANO-LGG criteria. To evaluate the impact of ONC201 treatment on health care resource utilization.

Study To Assess Efficacy Safety And Pharmacokinetics Of Iptacopan (LNP023) In Participants With Autoimmune Benign Hematological Disorders

All genders
Phase 2
Interventional
The main purpose of this study is to evaluate the efficacy and safety of the investigational drug iptacopan (LNP023) in people with primary ITP or primary CAD. You will be in the study about 6 months with the opportunity to extend the total duration to about 31 months if you …

UPCC 45421 Phase I/II study to reduce post-transplantation cyclophosphamide dosing for older or unfit patients undergoing bone marrow transplantation for hematologic malignancies

All genders
Certain blood cancers are treat blood or bone marrow transplants. Sometimes the donor cells attack the recipient's body, called GVHD. Cyclophosphamide helps reduce the risk and severity of GVHD .Researchers want to learn if using a lower dose of cyclophosphamide may reduce the drug's side effects while maintaining its effectiveness.
11 - 20 of 33